Compare · EW vs FOIL
EW vs FOIL
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Londian Wason New Energy Tech Inc. (FOIL): market cap, price performance, sector, and recent activity on the wire.
Summary
- EW operates in Health Care, while FOIL operates in Industrials - the two are in different parts of the market.
- EW is the larger of the two at $58.73B, about 53.7x FOIL ($1.09B).
- Over the past year, EW is up 21.5% and FOIL is down 44.5% - EW leads by 66.0 points.
- EW has hit the wire 8 times in the past 4 weeks while FOIL has been quiet.
- EW has more recent analyst coverage (25 ratings vs 0 for FOIL).
- Company
- Edwards Lifesciences Corporation
- Londian Wason New Energy Tech Inc.
- Price
- $102.13+1.34%
- $13.55-3.21%
- Market cap
- $58.73B
- $1.09B
- 1M return
- +21.24%
- -25.92%
- 1Y return
- +21.47%
- -44.51%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- 2026
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 0
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Londian Wason New Energy Tech Inc.
According to Frost&Sullivan, Londian Wason was the world's largest supplier of lithium-ion battery ('LiB') copper foil in terms of sales volume in 2025, holding a global market share of 7.6%. In 2025, the Company supplied approximately 111,985 metric tons of LiB copper foil, maintaining the world's largest annual sales volume. As an industry leader in the global electrolytic copper foil market, Londian Wason has established a high-quality and diversified global customer base, serving top global battery and electronic circuit manufacturers such as LG Energy Solution, Panasonic Industrial Materials, SK On, Samsung SDI, ATL, CATL, BYD, and Sunwoda. Londian Wason was the first copper foil manufacturer in China to successfully develop 6µm high-strength LiB copper foil and the first in the world to achieve mass production of 6µm copper foil.
Latest EW
- Edwards Lifesciences upgraded by Robert W. Baird with a new price target
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Third Quarter Results
- Edwards Lifesciences upgraded by Truist with a new price target
- CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System
- Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features
- FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease
- CVP, TAVR Lippis Daniel J. sold $53,017 worth of shares (619 units at $85.65) as part of a pre-agreed trading plan (SEC Form 4)
- Barclays initiated coverage on Edwards Lifesciences with a new price target
Latest FOIL
No recent items for Londian Wason New Energy Tech Inc..